Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 74

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 74
---
 develop next-generation therapies to help meet some of the most urgent medical needs.

Our programs target infectious diseases, including
antibiotic-resistant infections, and solid tumors, leveraging advanced lipid-based delivery systems to enhance the safety, efficacy,
and clinical utility of proven therapeutics and to uncover new clinically significant uses for established compounds. Our proprietary
technology builds on the same principles that made Doxil®, the first FDA-approved Nanomedicine using liposomal drug delivery, a success.
We apply these principles to treat infectious diseases and cancer by encapsulating potent therapeutics in novel lipid-based particles.
By encapsulating potent therapeutics within novel lipid-based particles, we achieve controlled drug release, targeted delivery, and extended
circulation time, ultimately leading to greater efficacy and fewer systemic side effects. Our planned clinical trials aim to expand the
therapeutic horizons of hard-to-treat diseases by amplifying, improving, and unleashing the potential of encapsulated therapeutics to
enhance delivery and achieve a controlled release. This includes antimicrobial resistance and solid tumors being as they are areas with
high unmet need.

Our core business strategy combines disciplined
product candidate development with strategic deployment of internal expertise and effective use of external resources. We leverage our
experienced executive management team and our established networks throughout the biopharmaceutical industry to identify and develop
product candidates that we believe can provide superior clinical benefits to patients living with life-threatening conditions.

Nanoparticle-based therapies involve using
tiny particles (nanoparticles) to deliver drugs or other therapeutic agents to specific locations in the body, often with the goal of
enhancing treatment effectiveness and minimizing side effects. These nanoparticles, typically ranging from 1 to 1000 nanometers
in size, can be engineered to encapsulate various therapeutic agents, including proteins, nucleic acids, or small molecule drugs. Compared
to conventional drugs, nanoparticle-based drug delivery has specific advantages, such as improved stability and biocompatibility, enhanced
permeability and retention effect, and improved targeting to diseased tissues such as tumors or sites of infection.

We are committed to addressing unmet medical
needs in antibiotic resistant microbial, oncology, and immunology through the development of lipid-based therapeutics. By combining established pharmacology with advanced lipid delivery systems, we aim to improve drug efficacy, optimize safety profiles, and enable targeted delivery—advancing treatment options where existing therapies are limited.

<div align='center'>44

Technology and Industry Overview. Market Opportunities</div>

Nanoparticles-based therapies,